X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUN PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUN PHARMA ABBOTT INDIA/
SUN PHARMA
 
P/E (TTM) x 40.2 37.6 106.8% View Chart
P/BV x 10.3 4.0 257.5% View Chart
Dividend Yield % 0.7 0.3 212.3%  

Financials

 ABBOTT INDIA   SUN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
SUN PHARMA
Mar-18
ABBOTT INDIA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110701 872.2%   
Low Rs3,996433 922.4%   
Sales per share (Unadj.) Rs1,552.2110.4 1,405.9%  
Earnings per share (Unadj.) Rs188.811.0 1,719.9%  
Cash flow per share (Unadj.) Rs196.417.2 1,140.1%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.4 308.5%  
Book value per share (Unadj.) Rs796.6158.8 501.6%  
Shares outstanding (eoy) m21.252,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.35.1 63.4%   
Avg P/E ratio x26.851.6 51.8%  
P/CF ratio (eoy) x25.732.9 78.2%  
Price / Book Value ratio x6.33.6 177.7%  
Dividend payout %29.118.2 159.9%   
Avg Mkt Cap Rs m107,3761,360,021 7.9%   
No. of employees `0003.317.8 18.7%   
Total wages/salary Rs m3,93753,671 7.3%   
Avg. sales/employee Rs Th9,929.314,890.9 66.7%   
Avg. wages/employee Rs Th1,185.13,017.1 39.3%   
Avg. net profit/employee Rs Th1,207.71,480.6 81.6%   
INCOME DATA
Net Sales Rs m32,985264,895 12.5%  
Other income Rs m1,1708,388 13.9%   
Total revenues Rs m34,155273,282 12.5%   
Gross profit Rs m5,24556,081 9.4%  
Depreciation Rs m16214,998 1.1%   
Interest Rs m385,176 0.7%   
Profit before tax Rs m6,21544,295 14.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m2,2038,452 26.1%   
Profit after tax Rs m4,01226,338 15.2%  
Gross profit margin %15.921.2 75.1%  
Effective tax rate %35.419.1 185.7%   
Net profit margin %12.29.9 122.3%  
BALANCE SHEET DATA
Current assets Rs m22,655316,359 7.2%   
Current liabilities Rs m6,681198,643 3.4%   
Net working cap to sales %48.444.4 109.0%  
Current ratio x3.41.6 212.9%  
Inventory Days Days6595 68.3%  
Debtors Days Days29108 27.1%  
Net fixed assets Rs m835213,178 0.4%   
Share capital Rs m2132,399 8.9%   
"Free" reserves Rs m16,715378,606 4.4%   
Net worth Rs m16,928381,006 4.4%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m24,162643,028 3.8%  
Interest coverage x163.79.6 1,712.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.4 331.4%   
Return on assets %16.84.9 342.0%  
Return on equity %23.76.9 342.9%  
Return on capital %36.910.0 368.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36940,816 0.9%   
Fx outflow Rs m3,80730,143 12.6%   
Net fx Rs m-3,43810,673 -32.2%   
CASH FLOW
From Operations Rs m1,52739,072 3.9%  
From Investments Rs m-2,148-33,708 6.4%  
From Financial Activity Rs m-1,024-15,393 6.7%  
Net Cashflow Rs m-1,646-7,359 22.4%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 5.1 154.0%  
FIIs % 0.1 23.0 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 8.3 206.0%  
Shareholders   18,270 133,026 13.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS